Compare Five Below Inc (FIVE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Organon & Co. Common Stock — how do they compare? Five Below Inc trades at $218.95 (market cap $11.75B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Five Below Inc is far larger — about 3.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Five Below Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Organon & Co. Common Stock for 0 Days on average.
| FIVE | OGN | |
|---|---|---|
Market Cap | $11.75B | $3.62B |
Volume | 742,657 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $13.81 |
52-Week Low | $147.05 | $5.70 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $12.60B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $218.95, up 2.51% today, with strong earnings momentum after beating Q1 and Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with 40.26% gross margins and 28.25% ROE. Recent news highlights growth initiatives including a $600M buyback and digital marketing push. Revenue growth accelerated from $3.6B in 2024 to $3.9B in 2025, with projected $5.3B in 2026.
FIVE presents a growth opportunity with analyst consensus target of $298.44 (36% upside), though execution risks remain. The premium valuation (P/E 19.14) requires sustained margin expansion amid consumer spending pressures. Institutional sentiment is bullish with 60% buy ratings, but technical weakness near resistance at $219 suggests near-term consolidation.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
